Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: A pilot study

Johanna W. Baars, Johanna C M Fonk, Riekeld J. Scheper, B. Mary E von Blomberg-van der Flier, Herman Bril, Paul v. d. Valk, Herbert M. Pinedo, John Wagstaff

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Tumour infiltrating lymphocytes (TIL) were isolated and expanded from biopsy samples of 4 patients with metastatic melanoma. The patients were treated with autologous expanded TIL and continuous or bolus infusion of Interleukin 2 (IL-2) at a dose of 18 × 106 International Units/m2/day for 5 days starting 36-48 hours after administration of cyclophosphamide at a dose of 1 g/m2. The number of TIL infused ranged from 1010 to 5,56 × 1010 cells. Two patients had stable disease (SD) lasting for 2 1/2 and 4 months respectively and they died 24 and 13 months after therapy. One patient died during therapy due to a pseudomonas septicaemia and another patient developed progressive disease (PD). He died 3 months after the start of therapy. The side effects were substantial but most of them were reversible upon cessation of the treatment. The majority of the expanded TIL of all patients were of the CD8+ phenotype. Cutaneous metastases from two patients, removed after treatment with IL-2 and TIL, showed moderate lymphocytic infiltration also mainly of CD8+ T cells. The treatment with IL-2 and TIL is feasible, but further investigations should continue in an attempt to improve the efficacy of the therapy, to reduce toxicity and to diminish the costs and labour of the culture methods.

Original languageEnglish (US)
Pages (from-to)289-297
Number of pages9
Issue number4
StatePublished - Dec 1992
Externally publishedYes


  • metastatic melanoma
  • sinterleukin-2
  • tumour infiltrating lymphocytes

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Treatment with tumour infiltrating lymphocytes and interleukin-2 in patients with metastatic melanoma: A pilot study'. Together they form a unique fingerprint.

Cite this